SpringWorks Therapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$49,301
$59,733
$21,006
$5,447
Gross Profit
45,960
57,280
19,075
4,487
EBITDA
-57,937
-44,077
-93,202
-97,925
EBIT
-58,815
-44,921
-93,931
-98,463
Net Income
-53,530
-39,919
-87,385
-94,322
Net Change In Cash
49,301
59,733
21,006
5,447
Free Cash Flow
-15,976
-54,015
-79,507
-60,403
Cash
84,456
79,898
118,031
176,053
Basic Shares
74,264
74,121
73,768
73,486

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$5,447
$6,147
$35,000
$35,000
Gross Profit
5,025
6,147
-490
34,651
EBITDA
-341,346
-279,909
-172,978
-45,975
EBIT
-343,013
-280,674
-173,468
-46,324
Net Income
-325,104
-274,160
-173,212
-44,244
Net Change In Cash
5,447
6,147
35,000
35,000
Free Cash Flow
-230,180
-171,759
-129,893
-32,833
Cash
176,053
67,490
103,961
147,089
Basic Shares
63,123
53,290
48,497
43,300

Earnings Calls

Quarter EPS
2024-09-30
-$0.72
2024-06-30
-$0.54
2024-03-31
-$1.18
2023-12-31
-$1.45